Загрузка...
Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study
BACKGROUND: Recent studies reported that sodium glucose cotransporter 2 (SGLT2) inhibitors reduced the cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) compared to placebo in contrast to no reduction with dipeptidyl peptidase 4 (DPP4) inhibitors. However, there...
Сохранить в:
| Опубликовано в: : | Cardiovasc Diabetol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5996551/ https://ncbi.nlm.nih.gov/pubmed/29895330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-018-0730-z |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|